Bedrijfsoverzicht
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical entity dedicated to the development of small-molecule product candidates designed for the treatment of oncology and obesity. The company specifically focuses on TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor currently undergoing Phase 1/2 clinical trials for the management of chronic myeloid leukemia. This organization operates within the Healthcare sector, specifically the Biotechnology industry, a classification that signifies a focus on research-intensive drug discovery and development rather than established commercialization of approved medications. With a total market capitalization of $6.07B and an employee count of 59, the company presents a valuation that appears substantial relative to its current operational footprint. The disparity between the $6.07B market cap and the N/A annual revenue figure indicates that the market is pricing in future potential from clinical milestones rather than current cash-flow generation, suggesting the company is valued on the expectation of future regulatory approvals and commercial success rather than existing sales performance.
Financiële gezondheid
The company reports N/A for revenue and N/A for revenue growth, while the Net Income for the trailing twelve months stands at $-96,207,000 and EBITDA at $-110,034,000. The absence of reported revenue combined with significant net losses reveals a cost structure typical of clinical-stage biotechs where R&D expenditures heavily outweigh any current commercial income. Free Cash Flow is recorded at $-55,480,500, which reflects a capital-intensive burn rate that limits immediate financial flexibility and necessitates reliance on external funding sources. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported at 0.0%, a standard presentation for entities with no revenue or where revenue is insufficient to calculate meaningful margins before heavy development costs. On the liability side, the company holds $1.02B in cash against only $919,000 in debt, resulting in a Debt to Equity ratio of 0.09. This stark contrast between liquid assets and minimal obligations suggests a highly conservative balance sheet with negligible leverage risk. The Current Ratio is an exceptionally high 62.41, indicating that the company possesses more than sixty-two times the current assets required to cover its short-term liabilities, effectively eliminating liquidity concerns. Return on Equity is -14.2% and Return on Assets is -9.9%, metrics that mathematically reflect the dilution of shareholder and asset value due to substantial accumulated losses rather than operational profitability.
Waarderingsbeoordeling
The P/E Ratio (TTM) is listed as N/A due to negative earnings, while the Forward P/E is -33.86, implying that analysts or data aggregators project continued negative earnings in the near term. The Price to Book ratio stands at 5.87, indicating that the market values the company at nearly six times its book value, a significant premium often found in biotechnology firms with valuable intellectual property pipelines despite current losses. The Price to Sales ratio is N/A and the EV/EBITDA is -45.95, figures that highlight the difficulty in applying traditional multiple-based valuation models to a pre-revenue company with negative EBITDA. The stock's trading range over the past year has been defined by a 52-Week High of $53.19 and a 52-Week Low of $2.14. Based on the available data points, the current valuation sits somewhere within this extreme historical volatility, though the specific current price is not explicitly provided in the source text to calculate the exact percentage distance from the highs or lows. The Beta is -0.38, a negative value that is highly anomalous for equities and suggests an inverse correlation to the broader market, meaning the stock theoretically moves in the opposite direction of the market index during periods of volatility.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, which precludes any analysis of whether earnings are growing faster or slower than revenue at this specific moment in the company's lifecycle. As the company does not currently pay dividends, the Dividend Yield is N/A and the Payout Ratio is 0.0%. Consequently, the company reinvests all available resources, including its substantial cash reserves, directly into research and development activities rather than distributing income to shareholders. This growth-at-all-costs approach is characteristic of clinical-stage biopharmaceuticals where capital deployment is prioritized to advance clinical trials and secure regulatory approval rather than generating immediate shareholder yield. The overall growth and income profile is defined by a lack of historical financial data due to the N/A growth rates and the complete absence of dividend income, leaving the company's performance entirely dependent on the successful progression of its product candidates through clinical phases.